R&D Swapping: AstraZeneca Lures Mackay From Pfizer To Head Global R&D
This article was originally published in The Pink Sheet Daily
Pfizer in turn appoints Mikael Dolsten, an ex-Wyeth executive, as its worldwide R&D president.
You may also be interested in...
Martin Mackay, who left AstraZeneca at the end of January after new CEO Pasqual Soriot eliminated his position as head of global R&D, is joining Alexion’s senior management team, even as the highly successful, rare disease-focused biotech seeks to put manufacturing woes behind it.
AstraZeneca's new CEO Pascal Soriot signaled significant change is afoot for the troubled drug maker by eliminating the jobs of R&D President Martin Mackay and Exec VP-Global Commercial Tony Zook.
AstraZeneca isn't the first to attempt to reinvigorate its R&D organization. But the group's pure-pharma focus means it relies more heavily than most of its peers on the success of this organizational and cultural overhaul.